Clinical Trial Update: CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing a CD19x22 CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19x22 CAR T-cell Therapy (CD19x22 CAR T-cell therapy)

Snippet

Sponsor: University of Colorado, Denver | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING